AbolfazilR, HosseiniM, GhanizadehA, GhaleihaA, TabriziM, RaznahanM, GolalizadehM, AkhondzadehS. Double-blind randomized parallel-group clinical trial of efficacy of the combination fluoxetine plus modafinil versus fluoxetine plus placebo in the treatment of major depression. Depress Anxiety, 28:297–302. 2011.
BrentD, EmslieG, ClarkeG, WagnerKD, AsarnowJR, KellerM, VitielloB, RitzL, IyengarS, AbebeK, BirmaherB, RyanN, KennardB, HughesC, DeBarL, McCrackenJ, StroberM, SuddathR, SpiritoA, LeonardH, MelhemN, PortaG, OnoratoM, ZelaznyJ. Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: The TORDIA randomized controlled trial. JAMA, 299:901–913. 2008.
4.
DunnV, GoodyerIM. Longitudinal investigation into childhood, adolescence-onset depression: Psychiatric outcome in early adulthood. Br J Psychiatry, 188:216–222. 2006.
5.
FeighnerJP, HerbsteinJ, DamloujiN. Combined MAOI, TCA and direct stimulant therapy of treatment-resistant depression. J Clin Psychiatry, 46:206–209. 1985.
6.
GreenhillLL, PliszkaS, DulcanMK, BernetW, ArnoldV, BeitchmanJ, BensonRS, BuksteinO, KinlanJ, McClellanJ, RueD, ShawJA, StockS. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry, 41,Suppl 2:26S–49S. 2002.
7.
HareEH, DominiakJ, SharpeL. Phenelsine and dexamphetamine in depressive illness: A comparative trial. BMJ, 1:9–12. 1962.
8.
HowlandRH. The use of dopaminergic and stimulant drugs for the treatment of depression. J Psychosoc Nurs Ment Health Serv, 50:11–14. 2012.
9.
HuffmanJC, SternTA. Using psychostimulants to treat depression in the medically ill. Prim Care Companion J Clin Psychiatry, 6:44–46. 2004.
10.
KeitnerGI, MansfieldAK. Management of treatment-resistant depression. Psychatr Clin North Am, 35:249–265. 2012.
11.
KerrCW, DrakeJ, MilchRA, BrazeauDA, SkretnyJA, BrazeauGA, DonnellyJP. Effects of methylphenidate on fatigue and depression: a randomized, double-blind, placebo-controlled trial. J Pain Symptom Manage, 43:68–77. 2012.
12.
MaaloufFT, AtwiM, BrentDA. Treatment-resistant depression in adolescents: review and updates on clinical management. Depress Anxiety, 28:946–954. 2011.
13.
PatkarAA, MassandPS, PaeCU, PeindlK, Hooper–WoodC, MannelliP, CicconeP. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression. J Clin Psychopharmacol, 26:653–656. 2006.
StotzG, WoggonB, AngstJ. Psychostimulants in the therapy of treatment-resistant depression. Dialogues Clin Neurosci, 1:165–174. 1999.
17.
WallingVR, PfefferbaumB. The use of methylphenidate in a depressed adolescent with AIDS. J Dev Behav Pediatr, 11:195–197. 1990.
18.
WhartonRN, PerelJM, DaytonPG, MalitzS. A potential clinical use for methylphenidate with tricyclic antidepressants. Am J Psychiatry, 127:1619–1625. 1971.
19.
WilkinsonP, DubickaB, KelvinR, RobertsC, GoodyerI. Treated depression in adolescents: predictors of outcome at 28 weeks. Br J Psychiatry, 194:334–341. 2009.
